Effects of cytokine deficiency on chemokine expression in CNS of mice with EAE

Journal of Neuroscience Research

Volumn 67, Issue 5, 2002, Pages 680-688

  Matejuk, Agata ^a   Dwyer, Jami ^b   Ito, Atsushi ^c   Bruender, Zachary ^a   Vandenbark, Arthur A ^a   Offner, Halina ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

^c INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

Chemokines; Cytokines; EAE MS; Rodent; Transgenic knockout

Indexed keywords

CHEMOKINE; CYTOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE DEFICIENCY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; KNOCKOUT MOUSE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEFICIENCY;

EID: 0036500173     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.10156     Document Type: Article

References (50)

1. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins
2. CCR5(+) and CXCK3(+) T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions
3. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice
4. Tumor necrosis factor alpha mRNA expression in early multiple sclerosis lesions: Correlation with demyelinating activity and oligodendrocyte pathology
5. Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis
6. Transgenic interleukin 10 prevents induction of experimental autoimmune encephalomyelitis
7. Severity of symptoms and demyelination in MOG-induced EAE depends on TNFR1
8. A critical role for IL-4 in regulating disease severity in experimental autoimmune encephalomyelitis as demonstrated by IL-4 deficient C57BL/6 mice and BALB/c mice
9. Mice with a disrupted IFN-γ gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE)
10. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis
11. Induction of experimental allergic encephalomyelitis in PL/J and (SJL/J × PL/J)F1 mice by myelin basic protein and its peptides: Localization of a second encephalitogenic determinant
12. Central nervous system gene therapy with interleukin-4 inhibits progression of ongoing relapsing-remitting autoimmune encephalomyelitis in Biozzi AB/H mice
13. Chemokine expression in GKO mice (lacking interferon-gamma) with experimental autoimmune encephalomyelitis
14. Chemokine expression in murine experimental allergic encephalomyelitis
15. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis
16. Expression of CSF-1, c-fms, and MCP-1 in the central nervous system of rats with experimental allergic encephalomyelitis
17. Interferon gamma, interleukin 4 and transforming growth factor beta in experimental autoimmune encephalomyelitis in Lewis rats: Dynamics of cellular mRNA expression in the central nervous system and lymphoid cells
18. Estrogen treatment downregulates TNF-α production and reduces the severity of experimental autoimmune encephalomyelitis in cytokine knockout mice
19. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2
20. An important role for the chemokine macrophage inflammatory protein-1 in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis
21. MIP-1 and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation
22. TNF accelerates the onset but does not alter the incidence and severity of myelin basic protein-induced experimental autoimmune encephalomyelitis
23. Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protien-1 alpha and monocyte chemotactic protein-1
24. Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting
25. Interferon-γ confers resistance to experimental allergic encephalomyelitis
26. Experimental autoimmune encephalomyelitis in IL-4 deficient mice
27. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination
28. Macrophage inflammatory protein-2 and KC induce chemokine production by mouse astrocytes
29. Tumor necrosis factor alpha and its receptors in relapsing-remitting multiple sclerosis
30. Cytokine therapy in immune-mediated demyelinating diseases of the central nervous system: A novel gene therapy approach
31. Reduced chemokine and chemokine receptor expression in spinal cords of TCR BV8S2 transgenic mice protected against experimental autoimmune encephalomyelitis with BV8S2 protein
32. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: An immunohistochemical and in situ hybridization study
33. Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein
34. The immunopathogenesis and regulation of T-cell-mediated demyelinating diseases
35. Astrocyte expression of mRNA encoding cytokines IP-10 andJE/MCP-1 in experimental autoimmune encephalomyelitis
36. Tumour necrosis factor alpha is elevated in serum and cerebrospinal fluid in multiple sclerosis and inflammatory neuropathies
37. Challenging cytokine redundancy: Inflammatory cell movement and clinical course of experimental autoimmune encephalomyelitis are normal in lymphotoxin-deficient, but not tumor necrosis factor-deficient, mice
38. Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent
39. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis
40. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination
41. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions
42. Local delivery, of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis
43. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients
44. Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protien-1alpha or its CCR5 receptor
45. IFN-gamma shapes immune invasion of the central nervous system via regulation of chemokines
46. Myelin proteolipid protein induces demyelinating disease in mice
47. Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions
48. Gender differences in autoimmune demyelination in the mouse: Implications for multiple sclerosis
49. IFN-γ plays a critical downregulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis
50. Acute and relapsing experimental autoimmune encephalomyelitis in IL-4- and α/β T cell-deficient C57BL/6 mice